Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Inhibitor of CDK and GSK
BML-EI310-0005 5 mg 295.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-270-274

Potent inhibitor of CDK1/cyclin B (IC50=400nM). Also inhibits CDK2/cyclin A (IC50=680nM) , CDK5 (IC50=850nM) and with much less effect other kinases. More recently, kenpaullone has been found to be a useful GSK-3β inhibitor (IC50=23nM). Induces pluripotency in somatic cells when used in combination with reprogramming factors. Increases neurogenesis of human neural progenitor cells through stimulation of Wnt/β-catenin signaling pathway.

Product Details

Alternative Name:9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5H)-one
Purity:≥98% (TLC)
Identity:Determined by 1H-NMR.
Appearance:Tan solid.
Solubility:Soluble in DMSO (>25mg/ml); insoluble in water or ethanol.
Shipping:Ambient Temperature
Long Term Storage:-20°C
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003), Abstract;
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem. 276, 251 (2001), Abstract;
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity: C. Kunick, et al.; Bioorg. Med. Chem. Lett. 10, 567 (2000), Abstract;
Inhibition of CDKs as a therapeutic modality: E.A. Sausville, et al.; Ann. NY Acad. Sci. 910, 207 (2000), Abstract;
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25: M. Leost, et al.; Eur. J. Biochem. 267, 5983 (2000), Abstract;
Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition: R. Gussio; Anticancer Drug Des. 15, 53 (2000), Abstract;
ATP-site directed inhibitors of cyclin-dependent kinases: N. Gray, et al.; Curr. Med. Chem. 6, 859 (1999), Abstract;
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases: D.W. Zaharevitz, et al.; Cancer Res. 59, 2566 (1999), Abstract;
Fused azepinones with antitumor activity: C. Kunick; Curr. Pharm. Des. 5, 181 (1999), (Review), Abstract;
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity: C. Schultz, et al.; J. Med. Chem. 42, 2909 (1999), Abstract;

Related Products

LEADING LIGHT® Wnt Reporter Assay Starter Kit 

Chemiluminescent cell-based assay for discovering Wnt pathway modulators
FUNC, Chemiluminescence, HTS | Print as PDF
ENZ-61001-0001 96 wells 1,248.00 USD
Do you need bulk/larger quantities?

β-Catenin ELISA kit 

ELISA, Colorimetric detection | Print as PDF
ADI-900-135 96 wells 733.00 USD
Do you need bulk/larger quantities?

β-Catenin monoclonal antibody (12F7) 

IHC, IP, WB | Print as PDF
ADI-KAM-ST001-E 100 µg 341.00 USD
Do you need bulk/larger quantities?

Related Literature

Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Stem Cells
Stem Cells
Download as PDF

Download as PDF

All new literature pieces